3Hofle G, Bedorf N, Gerth K, et al. Epothilone, Derenherstellungsverfahren sowie sie enthaltende mittel[P].German, patent disclosure DE 4138042, 1993.
4Bollag D, McQueney P, Zhu J, et alEpothilones, a new classof microtubule-stabilizing agents with a taxol-like mechanismof aciion^.Cancer Res, 1995, 55(11):2325-2333.
5Altmann KH. Epothilone B and its analogs-a newfamily of anticancer agents [J] .M.Rev Me dCAem,2003,3(2):149-158.
6Tommasi S, Mangia A,Lakalamita R, et al. Cytoskeletonand paclitaxel sensitivity in breast cancer.the role ofbeta-tubulins[J].Int J Cancer,2001, 120(10): 2078-2085.
7Jassem J,Fein L,Karwal M,ef al. Ixabepilone pluscapecitabine in advanced breast cancer patients withearly relapse after adjuvant anthracyclines and taxanes:A pooled subset analysis of two phase III studies[J].rAe2012,21:89-94.
8Chuang E, Wiener N, Christos P, et al. Phase I trial ofixabepilone plus pegylated liposomal doxorubicin inpatients with adenocarcinoma of breast or ovary daggerdouble dagger[J]. Ann Oncol, 2010, 21(10): 2075-2080.
9De Geest K, Blessing JA, Morris RT, et al. Phase IIclinical trial of ixabepilone in patients with recurrentor persistent platinum- and taxane-resistant ovarianor primary peritoneal Cancer: a gynecologic oncologygroup study[J] + J Clin Oncol, 2010, 28(1): 149-153.
10Buzdar AU.Clinical Experience with Epothilones inPatients with Breast CancQr[J].CIinical Breast CancerSupplement ,2008,8(2):71-78.
